2026-07-25 2026-07-25 , online online, 390 € zzgl. MwSt. Dr. Angela Vogt-Eisele https://forum-institut.de/seminar/26122664-recording-update-eu-pharma-legislation-environmental-risk-assessment-era/referenten/26/26_12/26122664-recording-update-eu-pharma-legislation-environmental-risk-assessment-era_vogt-eisele-angela.jpg Recording: Update EU Pharma Legislation - Environmental risk assessment (ERA)

This recording delivers a clear overview of the evolving ERA requirements under the EU pharmaceutical reform. In approximately 90 minutes, you will understand the current legal framework, the changes proposed in the new directive, how ERAs integrate into lifecycle management, and how to handle legacy compounds and other special cases.

Topics
  • Current legal framework and regulatory requirements
  • Why the current requirements are tightened
  • Changes and unknowns in the proposed directive
  • Integration of ERAs into lifecycle management
  • Handling of legacy compounds (authorised before 2006)
  • Special cases: Endocrine and persistent active substances
  • The role of antimicrobial resistance (AMR)


Who should attend
This course is designed for regulatory affairs professionals with a solid background in EU marketing authorisation procedures. Legal/compliance, quality, pharmacovigilance and related professionals involved in planning and implementing EU regulatory requirements will also benefit from this recording.
Aims and objectives
This recording of a live webcast series provides a structured, practice-oriented update on the EU pharmaceutical reform. The webcast consists of four individual modules, each approximately 90 minutes long, which are available separately or as a complete bundle at a reduced price. This course covers one module. The bundle "Update EU Pharma Legislation - The Full Series" can be found via the webcode 60012660.

The recording of this module provides a structured overview of the evolving Environmental Risk Assessment requirements under the EU pharmaceutical reform. In approximately 90 minutes, you will gain clarity on the current legal framework, the rationale behind the tightening of existing requirements, and the key changes and remaining unknowns in the proposed directive. The module also addresses the integration of ERAs into lifecycle management, the handling of legacy compounds authorised before 2006, and special cases such as endocrine and persistent active substances. By the end, you will be able to assess the ERA-related obligations relevant to your portfolio and identify the steps needed to ensure compliance under the new framework.

The recorded content is available to you flexibly - ideal for reviewing the topics at your own pace or looking up specific sections as needed. Access to the recording is available for 90 days after purchase.
Your benefit

  • Recording of a live webcast - for maximum flexibility and self-paced learning
  • Concise 90-minute format covering ERA requirements under the EU pharmaceutical reform
  • Clear overview of current requirements and the rationale behind their tightening
  • Guidance on integrating ERAs into lifecycle management and handling legacy compounds
  • Insights on special cases: endocrine and persistent active substances, and AMR
  • Understanding of the new transparency requirements and public access to ERA data

Recording: Update EU Pharma Legislation - Environmental risk assessment (ERA)

Recording: Update EU Pharma Legislation - Environmental risk assessment (ERA)

Benefits
  • Flexible format
  • Concise update in approximately 90 minutes
  • Complete webcast available at reduced price
  • Officially certified according to ISO 9001 and ISO 21001

Webcode 26122664

Jetzt buchen

JETZT Buchen

Referent


Gebühr
Ihre Kontaktperson

Jean-Marie Bayhurst
Konferenzmanager Pharma & Healthcare

+49 6221 500-685
j.bayhurst@forum-institut.de

Details

This recording delivers a clear overview of the evolving ERA requirements under the EU pharmaceutical reform. In approximately 90 minutes, you will understand the current legal framework, the changes proposed in the new directive, how ERAs integrate into lifecycle management, and how to handle legacy compounds and other special cases.

Topics

  • Current legal framework and regulatory requirements
  • Why the current requirements are tightened
  • Changes and unknowns in the proposed directive
  • Integration of ERAs into lifecycle management
  • Handling of legacy compounds (authorised before 2006)
  • Special cases: Endocrine and persistent active substances
  • The role of antimicrobial resistance (AMR)


Who should attend
This course is designed for regulatory affairs professionals with a solid background in EU marketing authorisation procedures. Legal/compliance, quality, pharmacovigilance and related professionals involved in planning and implementing EU regulatory requirements will also benefit from this recording.

Aims and objectives

This recording of a live webcast series provides a structured, practice-oriented update on the EU pharmaceutical reform. The webcast consists of four individual modules, each approximately 90 minutes long, which are available separately or as a complete bundle at a reduced price. This course covers one module. The bundle "Update EU Pharma Legislation - The Full Series" can be found via the webcode 60012660.

The recording of this module provides a structured overview of the evolving Environmental Risk Assessment requirements under the EU pharmaceutical reform. In approximately 90 minutes, you will gain clarity on the current legal framework, the rationale behind the tightening of existing requirements, and the key changes and remaining unknowns in the proposed directive. The module also addresses the integration of ERAs into lifecycle management, the handling of legacy compounds authorised before 2006, and special cases such as endocrine and persistent active substances. By the end, you will be able to assess the ERA-related obligations relevant to your portfolio and identify the steps needed to ensure compliance under the new framework.

The recorded content is available to you flexibly - ideal for reviewing the topics at your own pace or looking up specific sections as needed. Access to the recording is available for 90 days after purchase.

Your benefit

  • Recording of a live webcast - for maximum flexibility and self-paced learning
  • Concise 90-minute format covering ERA requirements under the EU pharmaceutical reform
  • Clear overview of current requirements and the rationale behind their tightening
  • Guidance on integrating ERAs into lifecycle management and handling legacy compounds
  • Insights on special cases: endocrine and persistent active substances, and AMR
  • Understanding of the new transparency requirements and public access to ERA data

Programm

Dr. Angela Vogt-Eisele

Environmental risk assessment (ERA)
  • Current legal framework and regulatory requirements
  • Why the current requirements are tightened
  • Changes and unknowns in the proposed directive
  • Integration of ERAs into lifecycle management
  • Handling of legacy compounds (authorised before 2006)
  • Special cases: Endocrine and persistent active substances
  • The role of antimicrobial resistance (AMR)
  • Transparency and public access to ERA data

Further details

Content

Environmental risk assessment (ERA) This course is a recorded module from a live webcast series held in June 2026. You will gain access to all content flexibly - ideal to go through the topics at your own pace or revisit specific sections as needed. Access to the recording is available for 90 days after purchase. The content reflects the status at the time of the event.

Complete Webcast Bundle

This module is also available as part of the complete four-module bundle "Update EU Pharma Legislation - The Full Series" at a reduced price.

The bundle includes the following modules:
  • The legal framework part 1 - overview and current procedural status
  • The legal framework part 2 - protection periods
  • Supply shortages and supply security
  • Environmental risk assessment (ERA)

More information can be found via the webcode 60012660.

This distinguishes our events

of 5 stars of all ratings from 2025

of 5 stars on Trustpilot = good

Recommendations

Hot Topics Regulatory Affairs

Diese Online-Tagung bietet einen umfassenden Einblick in die neusten Entwicklungen der EU-Pharmagesetzgebung, Variation ...

26. - 27.08.2026 in
Details

Global variations and lifecycle management

Global variations and lifecycle management - covering key regions: USA, Asia (China, Japan, South Korea), LATAM (Central...

31.08. - 21.09.2026 in
Details

Regulatory Affairs and GMP compliance in Eastern Europe

This online training offers comprehensive insights into Regulatory Affairs, CMC, and GMP requirements, with a focus on t...

26. - 27.08.2026 in
Details

Prozessvalidierung - Anforderungen an CMC-Daten

Prozessvalidierung - Das Intensivseminar zu den aktuellen regulatorischen Anforderungen. Sichern Sie sich jetzt Ihren Pl...

25.08.2026 in
Details

EU-Arzneimittelzulassung für Einsteiger*innen

In diesem Seminar erhalten Sie Know-how zur Zulassung von Arzneimitteln in Europa. Sie lernen, welche Zulassungswege mög...

25. - 28.08.2026 in
Details

Go forward

DEMO-Account e-Learning

Try out our e-Learning programmes free of charge and without any obligation.

Details
DEMO-Account e-Learning
We guarantee the highest quality

We are now officially certified to ISO 9001 and ISO 21001 standard.

Details
We guarantee the highest quality
Our rating in 2025

More than 3,700 customers have rated our training courses. Thank you for awarding us 4.4 stars out of 5.

Details
Our rating in 2025